- Home
- NWE vs ACAD Comparison
NWE vs ACAD Comparison
Compare NWE & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWE
- ACAD
- Stock Information
- Founded
- NWE 1923
- ACAD 1993
- Country
- NWE United States
- ACAD United States
- Employees
- NWE N/A
- ACAD N/A
- Industry
- NWE Power Generation
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- NWE Utilities
- ACAD Health Care
- Exchange
- NWE Nasdaq
- ACAD Nasdaq
- Market Cap
- NWE 3.5B
- ACAD 3.9B
- IPO Year
- NWE N/A
- ACAD 2004
- Fundamental
- Price
- NWE $68.25
- ACAD $25.17
- Analyst Decision
- NWE Hold
- ACAD Buy
- Analyst Count
- NWE 5
- ACAD 21
- Target Price
- NWE $59.80
- ACAD $29.00
- AVG Volume (30 Days)
- NWE 564.9K
- ACAD 1.6M
- Earning Date
- NWE 10-29-2025
- ACAD 11-05-2025
- Dividend Yield
- NWE 3.87%
- ACAD N/A
- EPS Growth
- NWE N/A
- ACAD 98.53
- EPS
- NWE 3.53
- ACAD 1.54
- Revenue
- NWE $1,569,761,000.00
- ACAD $1,047,118,000.00
- Revenue This Year
- NWE $6.08
- ACAD $14.12
- Revenue Next Year
- NWE $4.48
- ACAD $11.80
- P/E Ratio
- NWE $19.35
- ACAD $16.10
- Revenue Growth
- NWE 4.90
- ACAD 12.69
- 52 Week Low
- NWE $50.43
- ACAD $13.40
- 52 Week High
- NWE $68.48
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- NWE 73.73
- ACAD 66.30
- Support Level
- NWE $65.40
- ACAD $22.81
- Resistance Level
- NWE $67.23
- ACAD $23.98
- Average True Range (ATR)
- NWE 1.51
- ACAD 0.97
- MACD
- NWE 0.12
- ACAD 0.15
- Stochastic Oscillator
- NWE 99.64
- ACAD 100.00
About NWE NorthWestern Energy Group Inc.
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric utility operations, which include the generation, purchase, transmission, and distribution of electricity, and Natural Gas utility operations, which include the production, purchase, transmission, storage, and distribution of natural gas. The company uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric utility operations segment.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.